Will Medicare Cover Skyrizi?

If you have been prescribed Skyrizi and then opened your Medicare paperwork, first of all: deep breaths. Second of all: maybe a snack. Prescription coverage questions have a special talent for turning normal people into accidental insurance detectives. The good news is that Medicare often does cover Skyrizi. The less fun news is that the answer depends on how you get the drug, which Medicare coverage you have, and what rules your plan attaches to it.

In plain English, here is the big picture: self-injected Skyrizi is usually a Medicare Part D issue, while Skyrizi given by IV infusion in a medical setting may be handled under the medical benefit, which can mean Part B under Original Medicare or the medical side of a Medicare Advantage plan. So yes, Medicare may cover Skyrizi, but you need to know where your specific prescription fits before you can guess what you will owe.

What Is Skyrizi, and Why Does Medicare Treat It Like a Complicated Guest List?

Skyrizi is the brand name for risankizumab-rzaa, a biologic medication used to treat inflammatory conditions including plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. It works by targeting interleukin-23, a protein involved in inflammation. That is the scientific version. The human version is this: it is designed to help calm down an immune system that has been acting like it drank three espressos and chose chaos.

Coverage gets tricky because Skyrizi is not used the same way for every condition. For plaque psoriasis and psoriatic arthritis, it is typically given as a self-administered injection after the starting doses. For Crohn’s disease and ulcerative colitis, treatment includes induction infusions first, followed by maintenance treatment you continue on a schedule afterward. That difference matters because Medicare often separates coverage based on whether a drug is self-administered or administered by a provider.

The Short Answer: Will Medicare Cover Skyrizi?

Usually, yesbut not automatically, and not the same way for everyone.

Many Medicare drug plans cover Skyrizi, and it appears on a number of Medicare formularies. But “covered” does not always mean “easy,” and it definitely does not always mean “cheap.” Your plan may put Skyrizi on a specialty tier, require prior authorization, apply quantity limits, or ask for step therapy before approval. In other words, Medicare may open the door, but your plan may still ask for ID, a note from your doctor, and probably your emotional resilience.

Which Part of Medicare Covers Skyrizi?

Part D: The usual home for self-injected Skyrizi

If you take Skyrizi as a medication you inject yourself at home, coverage is usually handled under Medicare Part D. That includes:

• stand-alone Part D plans paired with Original Medicare, or
• Medicare Advantage plans that include prescription drug coverage.

This is the most common scenario for people using Skyrizi for plaque psoriasis or psoriatic arthritis, and often for the maintenance phase of Crohn’s disease or ulcerative colitis after the infusion stage is done.

If you have Original Medicare only and no Part D plan, self-injected Skyrizi is where things can go sideways fast. Original Medicare does not generally function as your retail prescription drug plan. So if your Skyrizi is meant to be obtained through a pharmacy or specialty pharmacy, you typically need Part D coverage for meaningful help.

Part B: Sometimes relevant for infusion-based treatment

For people receiving Skyrizi by IV infusion in a clinical setting, coverage may be handled under the medical benefit. Under Original Medicare, that may mean Part B, because Part B generally covers certain drugs that are administered by a provider and are not usually self-administered.

This matters most for Crohn’s disease and ulcerative colitis, where the induction phase starts with infusions. In real life, this can create a split-coverage situation: the infusion phase may be billed one way, and the maintenance injections may later be billed another way. So if you are asking whether Medicare covers Skyrizi, the smartest follow-up question is not just “yes or no?” but “which part of my treatment is being covered under which benefit?”

How Much Will Skyrizi Cost With Medicare?

This is where the answer gets personal. Your cost depends on your plan, your drug tier, your deductible, whether you get Extra Help, whether the claim runs through Part B or Part D, and whether you hit the yearly out-of-pocket cap for covered Part D drugs.

For Part D in 2026, Medicare now offers a much more predictable ceiling than in the past. Covered out-of-pocket spending is capped at $2,100 for the year. That is a very big deal for expensive biologics like Skyrizi. Also, the maximum Part D deductible in 2026 is $615, though some plans set a lower deductible or none at all.

That does not mean your first fill will feel adorable and wallet-friendly. High-cost specialty drugs can still hit hard early in the year before you move through your plan’s cost-sharing structure. But unlike the old “surprise, the year is ruined” model, there is now a clearer ceiling on what you can pay out of pocket for covered Part D drugs.

If Skyrizi is billed under Part B instead, your costs can look different. Under Original Medicare, people usually pay the Part B deductible and then coinsurance on covered Part B services unless they have Medigap or other supplemental protection. That is why the exact route of administration matters so much. Same drug, very different billing mood.

Why One Medicare Patient Pays More Than Another

Two people can both say, “Medicare covers my Skyrizi,” and still have completely different bills. Here are the usual reasons:

• Drug tier: Skyrizi is often placed on a specialty or higher-cost tier.
• Utilization rules: Prior authorization, quantity limits, or step therapy can slow approval and affect timing.
• Plan design: Different Part D and Medicare Advantage plans negotiate different formularies and cost-sharing.
• Type of Medicare coverage: Original Medicare plus Part D is not the same as Medicare Advantage with drug coverage.
• Extra Help status: Low-income subsidy can reduce premiums, deductibles, and prescription costs.
• Supplemental coverage: If a dose is billed under Part B, Medigap can change your out-of-pocket exposure.

This is why copying your neighbor’s plan because “they like it” is not always a winning strategy. Your drugs matter more than their enthusiasm.

What Rules Can Medicare Plans Put on Skyrizi?

Even when a Medicare plan covers Skyrizi, the plan may still use common pharmacy-management rules. These include:

• Prior authorization: Your doctor may need to prove the drug is medically necessary.
• Step therapy: Your plan may want evidence that you tried other treatments first.
• Quantity limits: The plan may control how much can be dispensed at one time.

None of this means you are doomed. It just means the paperwork portion of your healthcare journey may briefly audition for a supporting role in your life.

Your doctor’s office usually plays a big role here. They may need to send chart notes, diagnosis details, prior treatment history, lab information, or documentation showing why Skyrizi is appropriate for your condition.

Can Medicare Advantage Cover Skyrizi?

Yes. If you are enrolled in a Medicare Advantage plan with drug coverage, Skyrizi may be covered through that plan’s pharmacy benefit for self-administered doses and through the medical benefit for infusion-based care, depending on your treatment phase and plan structure.

The main thing to remember is that Medicare Advantage plans are run by private insurers approved by Medicare. They follow Medicare rules, but the plan details still vary. Formularies vary. Networks vary. Specialty pharmacy arrangements vary. Even the hoops vary. Some hoops are smaller and made of fire.

What If Your Plan Says No?

A denial is frustrating, but it is not necessarily the end of the road. Medicare drug plans have an appeals process, and patients can also request a formulary exception in certain situations. If your plan denies Skyrizi, ask these questions right away:

1. Was it denied because the drug is not on the formulary?
2. Was it denied because prior authorization paperwork was incomplete?
3. Did the plan want proof that other drugs were tried first?
4. Can your doctor request an exception or file an appeal?

Appeals work best when the doctor’s office is specific. A good appeal explains your diagnosis, past treatment failures, side effects, medical need, and why the requested drug is appropriate. In other words, the appeal should read less like “pretty please” and more like “here is the clinical logic, the records, and the receipts.”

Can You Use a Skyrizi Savings Card With Medicare?

Generally, no. Manufacturer copay cards for Skyrizi are aimed at eligible commercially insured patients, not people whose drugs are paid for under Medicare or other government-funded programs. That is a common disappointment for Medicare beneficiaries, because the commercial ads make the savings sound easy and shiny.

That does not mean you have zero options. If your Skyrizi costs still feel crushing, look into:

• Extra Help through Medicare,
• state pharmaceutical assistance programs if available where you live,
• independent charitable foundations for eligible patients,
• and the Medicare Prescription Payment Plan, which lets you spread out covered drug costs across the calendar year.

Important note: the Medicare Prescription Payment Plan helps with cash flow. It does not reduce the total you owe. Think of it as a budgeting tool, not a magic discount wand.

How to Check if Your Specific Plan Covers Skyrizi

If you want the fastest path to a useful answer, do these five things:

1. Check your plan’s current formulary for Skyrizi or risankizumab-rzaa.
2. Look at the drug tier and any notes about prior authorization, step therapy, or quantity limits.
3. Ask whether your dose is being processed under the pharmacy benefit or the medical benefit.
4. Confirm which specialty pharmacy or infusion provider is in-network.
5. Ask your prescriber’s office to verify benefits before the first fill or infusion.

If you are comparing plans during Medicare enrollment season, do not just ask, “Does this plan cover Skyrizi?” Ask, “What tier is it on, what are the rules, and what would I likely pay in the first month and for the year?” Those are not the same question, and Medicare loves when people learn that the hard way.

What Real-Life Medicare Experiences With Skyrizi Often Look Like

For many people, the Skyrizi-and-Medicare experience does not feel dramatic at first. It usually starts with a doctor saying, “This may be a good option for you,” and a patient thinking, “Great, finally, a plan.” Then the insurance portion arrives and says, “Wonderful. Now let us all participate in an administrative scavenger hunt.”

A common experience is that the prescription gets written quickly, but the approval takes longer. The doctor’s office sends a prior authorization. The plan asks for diagnosis details. Then it may ask what other therapies were tried before. Then the specialty pharmacy calls. Then another call comes from the plan. Then someone asks whether the first phase is infusion-based or injection-based. At that point, many patients discover that “Will Medicare cover Skyrizi?” is really shorthand for a bigger question: “Who is billing what, under which benefit, through which vendor, and on what timeline?”

For people with psoriasis or psoriatic arthritis, the path can be a little cleaner because the treatment is usually self-injected and handled through the pharmacy side. Even then, patients often describe the same pattern: approval first, specialty pharmacy coordination second, delivery scheduling third, and then careful attention to out-of-pocket costs. Because Skyrizi is expensive, the first bill can be a real shock before the yearly Part D cap starts doing its job. Many people are relieved to learn there is now a yearly ceiling on covered Part D spending, even if the first part of the year still feels financially rude.

For people with Crohn’s disease or ulcerative colitis, the experience can be even more confusing because induction infusions and maintenance injections may not travel through the same insurance lane. One part of treatment may look like medical billing, while the next part behaves like pharmacy billing. Patients sometimes think the plan changed its mind, when really the billing category changed. That distinction is not always explained clearly, which is unfortunate, because nothing says “relax and heal” like having to decode benefit design while managing a chronic condition.

Another very real experience is the emotional side of all this. People are not just choosing a medication; they are trying to control symptoms, protect their quality of life, and avoid flares, pain, skin symptoms, joint problems, or bathroom-related disasters that do not exactly improve one’s social calendar. So when Medicare coverage is delayed or unclear, the stress is not abstract. It is personal. It affects treatment timing, budgeting, and peace of mind.

The smoother experiences usually happen when three things line up early: the prescriber’s office is proactive, the patient knows whether the drug is being processed under Part B or Part D, and the plan’s rules are confirmed before treatment starts. The rougher experiences usually involve surprisesunexpected tier placement, missing paperwork, confusion over infusion versus injection coverage, or the mistaken assumption that a manufacturer savings card will work for Medicare. In short, the most helpful strategy is boring but effective: verify everything early, keep records, ask for written confirmation when possible, and do not be shy about appealing a denial.

Final Verdict

Yes, Medicare often covers Skyrizi, but the details matter a lot. If Skyrizi is self-administered, it is usually covered through Part D or a Medicare Advantage drug plan. If it is given by infusion in a medical setting, it may be covered under the medical benefit, which can involve Part B under Original Medicare. Costs can still be significant, but current Medicare rules make the financial picture more predictable than it used to be, especially for covered Part D drugs.

The smartest move is to verify your exact plan rules before treatment begins. Check the formulary. Confirm the billing path. Ask about prior authorization. And if your first answer is “no,” treat that as the beginning of the conversation, not the end of it.